This is a bi-centric, prospective randomized study to evaluate the contribution of rapid echocardioscopy at the patient's bedside to improving the prognosis of patients hospitalized for acute heart failure. The following markers will be evaluated: sST2, Copeptin, chromogranin, NGAL, suPAR and cystatin.
The JECICA study is the first prospective randomized study to evaluate the contribution of rapid echocardioscopy at the patient's bedside to improving the prognosis of patients hospitalized for acute heart failure (paper submitted to the American Heart Journal, Impact Factor 4.15). The serum library set up to consider this ancillary study can now be used. With it, a comparative analysis of the expression profiles of emerging biological markers will be made according to whether patients received standard management or the "Jet Echo" strategy. The following markers will be evaluated: sST2, Copeptin, chromogranin, NGAL, suPAR and cystatin. This study should help to explain any differences in results observed, consider the development of multiparametric prognostic scores and explore the correlation between biological markers and the evaluation of echocardiographic congestion from a pathophysiological viewpoint. The results obtained should lead us to improve our usual practices for the management of heart failure patients.
Study Type
OBSERVATIONAL
Enrollment
169
The evolution of sST2, copeptin, chromogranin, NGAL, suPAR and cystatin will be evaluated between Day 0 and Month 1
Nîmes University Hospital
Nîmes, Gard, France
Montpellier University Hospital, Arnaud de Villeneuve
Montpellier, Hérault, France
Evolution of the emerging biological marker sST2 in plasma samples from the Jet Echo group.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker sST2 in plasma samples from the Jet Echo group.
Quantitative, ng/mL
Time frame: 1 Month
Evolution of the emerging biological marker sST2 in plasma samples from the conventional management group.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker sST2 in plasma samples from the conventional management group.
Quantitative, ng/mL
Time frame: 1 Month
Evolution of the emerging biological marker copeptin in plasma samples from the Jet Echo group
Quantitative, pmol/L
Time frame: Day 0
Evolution of the emerging biological marker copeptin in plasma samples from the Jet Echo group
Quantitative, pmol/L
Time frame: Month 1
Evolution of the emerging biological marker copeptin in plasma samples from the conventional management group
Quantitative, pmol/L
Time frame: Day 0
Evolution of the emerging biological marker copeptin in plasma samples from the conventional management group
Quantitative, pmol/L
Time frame: Month 1
Evolution of the emerging biological marker chromogranin in plasma samples from the Jet Echo group
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker chromogranin in plasma samples from the Jet Echo group
Quantitative, ng/mL
Time frame: Month 1
Evolution of the emerging biological marker chromogranin in plasma samples from the conventional management group
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker chromogranin in plasma samples from the conventional management group
Quantitative, ng/mL
Time frame: Month 1
Evolution of the emerging biological marker NGAL in plasma samples from the Jet Echo group.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker NGAL in plasma samples from the Jet Echo group.
Quantitative, ng/mL
Time frame: Month 1
Evolution of the emerging biological marker NGAL in plasma samples from the conventional management group.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker NGAL in plasma samples from the conventional management group.
Quantitative, ng/mL
Time frame: Month 1
Evolution of the emerging biological marker suPAR in plasma samples from the Jet Echo group.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker suPAR in plasma samples from the Jet Echo group.
Quantitative, ng/mL
Time frame: Month 1
Evolution of the emerging biological marker suPAR in plasma samples from the conventional management group.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker suPAR in plasma samples from the conventional management group.
Quantitative, ng/mL
Time frame: Month 1
Evolution of the emerging biological marker cystatin in plasma samples from the Jet Echo group.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker cystatin in plasma samples from the Jet Echo group.
Quantitative, ng/mL
Time frame: Month 1
Evolution of the emerging biological marker cystatin in plasma samples from the conventional management group.
Quantitative, ng/mL
Time frame: Day 0
Evolution of the emerging biological marker cystatin in plasma samples from the conventional management group.
Quantitative, ng/mL
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Sex
The sex of participants will be noted as Male/Female
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Sex
The sex of participants will be noted as Male/Female
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Age
The age of participants will be noted in years
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Age
The age of participants will be noted in years
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Diuresis
The diuresis of participants will be measured in millilitres
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Diuresis
The diuresis of participants will be measured in millilitres
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Diuresis
The diuresis of participants will be measured in millilitres
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Diuresis
The diuresis of participants will be measured in millilitres
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: blood pressure
The blood pressure of participants will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: blood pressure
The blood pressure of participants will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: blood pressure
The blood pressure of participants will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: blood pressure
The blood pressure of participants will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: heart rate
The heart rate of participants will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: heart rate
The heart rate of participants will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: heart rate
The heart rate of participants will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: heart rate
The heart rate of participants will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: risk factors
Cardiovascular risk factors (hypertension, diabetes, dyslipidemia, heredity) will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: risk factors
Cardiovascular risk factors (hypertension, diabetes, dyslipidemia, heredity) will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: risk factors
Cardiovascular risk factors (hypertension, diabetes, dyslipidemia, heredity) will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: risk factors
Cardiovascular risk factors (hypertension, diabetes, dyslipidemia, heredity) will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: history
The history and etiology of the heart disease (ischemic dilated, rhythmic, valvular, toxic, alcoholic) will be noted.
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: history
The history and etiology of the heart disease (ischemic dilated, rhythmic, valvular, toxic, alcoholic) will be noted.
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: history
The history and etiology of the heart disease (ischemic dilated, rhythmic, valvular, toxic, alcoholic) will be noted.
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: history
The history and etiology of the heart disease (ischemic dilated, rhythmic, valvular, toxic, alcoholic) will be noted.
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Left ventricle Ejection Fraction
The Left ventricle Ejection Fraction will be measured as a %.
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Left ventricle Ejection Fraction
The Left ventricle Ejection Fraction will be measured as a %.
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Left ventricle Ejection Fraction
The Left ventricle Ejection Fraction will be measured as a %.
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Left ventricle Ejection Fraction
The Left ventricle Ejection Fraction will be measured as a %.
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: renal insufficiency stage
The stage of renal insufficiency (urea, creatinine, Calcium-Dependent Protein Kinase clearance) will be measured.
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: renal insufficiency stage
The stage of renal insufficiency (urea, creatinine, Calcium-Dependent Protein Kinase clearance) will be measured.
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: renal insufficiency stage
The stage of renal insufficiency (urea, creatinine, Calcium-Dependent Protein Kinase clearance) will be measured.
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: renal insufficiency stage
The stage of renal insufficiency (urea, creatinine, Calcium-Dependent Protein Kinase clearance) will be measured.
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: New York Heart Association stage
The New York Heart Association stage will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: New York Heart Association stage
The New York Heart Association stage will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: New York Heart Association stage
The New York Heart Association stage will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: New York Heart Association stage
The New York Heart Association stage will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Type of heart failure
The type of heart failure (congestive heart failure/left heart failure/right heart failure) will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Type of heart failure
The type of heart failure (congestive heart failure/left heart failure/right heart failure) will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Type of heart failure
The type of heart failure (congestive heart failure/left heart failure/right heart failure) will be noted
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Type of heart failure
The type of heart failure (congestive heart failure/left heart failure/right heart failure) will be noted
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Type of therapy
The therapy given (Beta-blocker, ACE inhibitor, ARB2, Anti aldosterone, diuretics) and dosage, Implantable cardiac device, pacemaker will be noted.
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the Jet Echo group: Type of therapy
The therapy given (Beta-blocker, ACE inhibitor, ARB2, Anti aldosterone, diuretics) and dosage, Implantable cardiac device, pacemaker will be noted.
Time frame: Month 1
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Type of therapy
The therapy given (Beta-blocker, ACE inhibitor, ARB2, Anti aldosterone, diuretics) and dosage, Implantable cardiac device, pacemaker will be noted.
Time frame: Day 0
Correlation between emerging biomarkers and clinical symptomatology in the conventional management group: Type of therapy
The therapy given (Beta-blocker, ACE inhibitor, ARB2, Anti aldosterone, diuretics) and dosage, Implantable cardiac device, pacemaker will be noted.
Time frame: Month 1